Navigation Links
Why Some Vaccines May Require A Booster

ROCHESTER, N.Y., Nov. 27 /PRNewswire-USNewswire/ -- Preventing disease is the goal of every health care provider and fortunately every year, new vaccines are being added to assist in disease prevention. But do all vaccines boost immunity for the same period of time? And, if not, when are additional 'booster shots' needed to keep immunity strong?

In this month's issue of Pediatrics, the Journal of the American Academy of Pediatrics, Michael Pichichero MD, Director of the Rochester General Research Institute, based at Rochester General Hospital in Rochester NY, studies the medical necessity for occasional booster shots to sustain immunity.

It is a well known medical fact that a booster shot for tetanus is needed every 10 years to maintain your immunity. But, what happens if you fail to get that booster? "Fortunately, a patient has a window of opportunity to get a booster shot even after getting a dirty wound," said Dr. Pichichero. "In this case, the booster shot will take hold before the tetanus infection can establish itself. The problem is that this scenario is not true for all diseases."

In his published study, Dr. Pichichero, an international authority on vaccines and vaccine-induced memory, discusses the effectiveness of booster vaccinations and disease progression. "We found that for slow moving infections like hepatitis, immune memory is activated within plenty of time to prevent the disease after a person has been vaccinated and booster vaccines are not needed" said Dr. Pichichero. "Other examples of vaccines that do not appear to require boosters because the pace of disease progression is slow include: polio, measles, mumps, and German measles."

Dr. Pichichero Study

The study found, however, that there are several newer vaccines that may require booster shots to remain effective during a lifetime, including vaccines for diphtheria, all three types of spinal meningitis caused by bacteria, and the new vaccine to prevent cervical cancer. "Booster shots are needed in these cases because the disease progression is too fast for the memory response to occur in time," said Dr. Pichichero.

The study offers several important findings. "Pediatricians and family doctors must begin to anticipate the need to provide booster vaccinations for several of the newer vaccines introduced in recent years," said Dr. Pichichero. "And, public health agencies, such as the Centers for Disease Control, must begin to consider the cost of booster shots as they calculate the cost-benefit of vaccines. Up to now, cost calculations for the introduction and public payment of meningitis vaccines and the cervical cancer vaccine have not included the need (and cost) of periodic boosters, nor the consequences of missed boosters with disease development later in life."

While the article has a strong and clear scientific basis, Dr. Pichichero acknowledges that only continued monitoring will determine whether he is correct in his assessment of the need for booster shots for certain diseases. "We do not want to face a diphtheria epidemic in the U.S. as occurred in Russia a decade ago due to lack of boostering of adults," said Dr. Pichichero.

Dr. Pichichero was a member of the discovery team of the first bacterial spinal meningitis vaccine against Haemophilus influenzae type b, commonly called Hib; and participated in the foundational studies of the second spinal meningitis vaccine against pneumococci called Prevnar; and the third spinal meningitis vaccine against meningococcus called Menactra. He was an early champion for the introduction of safer whooping cough vaccines, called acellular vaccines. He has ongoing support from the National Institutes of Health to study the prospects of an ear, sinus and bronchitis vaccine. He has also received financial support for his research from vaccine companies including GlaxoSmithKline, MedImmune, Sanofipasteur and Wyeth (now Pfizer).

Rochester General Health System (RGHS) has been serving the community of Greater Rochester and beyond for more than 160 years and has earned national recognition for excellence in a variety of clinical specialties. Rochester General Hospital, the flagship of the system, is a 528-bed tertiary care facility that treats more Monroe County patients than any other hospital in the area. It is the fourth largest cardiac center in New York State and has been recognized as one of the nation's 100 Top Cardiovascular Hospitals eight times. RGHS also includes Newark-Wayne Community Hospital, a 120-bed facility primarily serving Wayne County; two long-term care facilities - Hill Haven and DeMay Living Center; a Medical Group consisting of more than 40 practices spread throughout Monroe and Wayne Counties; a Behavioral Health Network that provides adult and pediatric care; and Independent Living for Seniors (ILS), a program for seniors designed to enable the frail elderly to live in their own home, served by a network of supportive services

This news release was issued on behalf of Newswise(TM). For more information, visit

SOURCE Rochester General Health System

Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. DIA Conference to Explore Components of Risk Management Plans As They Apply to Medicinal Products, Therapeutic Biologics and Vaccines
2. Statement by Dr. Daniel Carucci, Vice President for Global Health for the United Nations Foundation on the Launch of the State of the World's Vaccines and Immunization Report
3. Tylenol May Weaken Effectiveness of Kids Vaccines
4. Acetaminophen May Weaken Effectiveness of Kids Vaccines
5. Injectable Vaccines More Effective for Adult Flu Than Nasal Sprays
6. Reportlinker Adds Vaccines 2009: World Market Analysis, Key Players, and Critical Trends in a Fast-Changing Industry Report
7. Equity Capital Management H1N1 Vaccines and Hard to Treat Diseases (HTDS)
8. DOR BioPharma Announces $9.4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines
9. More Teens Getting Needed Vaccines
10. Wellcome Trust and Merck launch joint venture to develop affordable vaccines
11. FDA Approves Vaccines for 2009 H1N1 Influenza Virus
Post Your Comments:
(Date:12/1/2015)... NY (PRWEB) , ... December 01, 2015 , ... ... non-traumatic limb amputations in the United States. Podiatrists are well aware that psychology-based ... adopt therapeutic behaviors) are often catastrophic contributors to diseases of the diabetic foot. ...
(Date:12/1/2015)... ... December 01, 2015 , ... For the ... is why Hollister Incorporated has launched the VaPro Plus Pocket™ touch free hydrophilic ... the VaPro touch free catheter portfolio,” said Michael Gresavage, Vice President North America. ...
(Date:12/1/2015)... ... December 01, 2015 , ... Next IT Healthcare, the leader ... in this year’s Fierce Innovation Awards: Healthcare Edition, an awards program from the ... finalist in the category of Digital Solutions for its innovative, industry-leading product, Alme ...
(Date:12/1/2015)... ... 2015 , ... TCS Healthcare Technologies (TCS), a leading provider ... is pleased to announce that VIP Care Services, a Caprock Health Group affiliate ... Complete Care™ Management to back their collaborative catastrophic case management initiatives. ACUITY Complete ...
(Date:12/1/2015)... GA (PRWEB) , ... December 01, 2015 , ... ... supports SACC-GA and SACC-USA through membership and leadership since 2008. Gary ... Chair for SACC-USA . Gary has spent a significant amount of time ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... BOSTON , December 1, 2015 Russia ... phase III clinical trials. 70% of new drugs registered in ... trials in Russia . --> Russia has ... trials. 70% of new drugs registered in Europe ... . --> Russia has always been ...
(Date:12/1/2015)... , Dec. 1, 2015 Relmada Therapeutics, Inc. ... treatment of chronic pain, announced today that the company will ... be held December 1-3 at the Luxe Sunset Boulevard Hotel ... Traversa , CEO of Relmada Therapeutics, will present on Thursday, ... Time). . Please register at least 10 ...
(Date:12/1/2015)...   MabVax Therapeutics Holdings, Inc . (OTCQB: MBVX), ... filed an Investigational New Drug Application (IND) with the ... lead fully human antibody product HuMab 5B1 as a ... initiate the Phase I clinical trial early in 2016. ... The planned Phase I trial will evaluate the safety, ...
Breaking Medicine Technology: